MEK162 and mFOLFIRI
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced KRAS Positive Metastatic Colorectal Cancer
Conditions
Advanced KRAS Positive Metastatic Colorectal Cancer
Trial Timeline
Aug 19, 2016 → Dec 21, 2022
NCT ID
NCT02613650About MEK162 and mFOLFIRI
MEK162 and mFOLFIRI is a phase 1 stage product being developed by Pfizer for Advanced KRAS Positive Metastatic Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02613650. Target conditions include Advanced KRAS Positive Metastatic Colorectal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02613650 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced KRAS Positive Metastatic Colorectal Cancer